Jeffrey Brewer discusses Bigfoot Biomedical’s Automated Insulin Delivery System

Bigfoot Biomedical has developed a fully functioning, automated insulin delivery solution for the treatment of Type 1 Diabetes (T1D). By integrating its FDA-approved insulin pump and the leading continuous glucose monitor (CGM) with a smartphone app and a comprehensive, cloud-based data platform, Bigfoot enables a safer and less costly way to treat the millions of people living with T1D. Founded by proven entrepreneurs with track records of innovation and value creation, Bigfoot is creating a durable business of scale, and meeting an important unmet health need. Bigfoot’s roots were chronicled in Wired Magazine and its prototype system, which has been used in the real-world for the past two years, was described poignantly in this blog post by the wife of Bigfoot’s co-founder Bryan Mazlish. Bigfoot was also recently featured in the WSJ.

Jeffrey Brewer is a Founder and CEO of Bigfoot Biomedical, a Silicon Valley company developing the world’s first automated system for the treatment of T1D. For the past thirteen years, since his son’s T1D diagnosis at age seven, Jeffrey has been a thought leader and influencer across the T1D community. As a volunteer, donor, and International Board Member for JDRF, he launched the JDRF Artificial Pancreas Project in 2005, and later served as CEO of JDRF. In the role of CEO, Jeffrey forged financial partnerships with industry to drive research and development of insulin delivery and glucose monitoring technologies. He spearheaded US regulatory reform in the area of automated insulin delivery, and elevated the organization’s strategic priorities to include health care policy, reimbursement, and access to technology for people with T1D. Prior to his work in T1D, Jeffrey founded two successful technology start-ups – CitySearch and Overture / GoTo.com – both of which later became publicly traded companies. Jeffrey served as CEO of Overture which was acquired by Yahoo! in 2002.

Below Content Ad